MGC Pharmaceuticals Limited board also advises that Mr. Evan Hayes has resigned from his position as a non-executive director of the Company, effective 1 January 2023, as part of the Company's transition to a dedicated life sciences pharmaceuticals company. As a result of Mr. Hayes' departure, MGC's board will be reduced to 5 directors, with the Company continuing to evaluate the composition of the board over the next 6 months to ensure that it reflects its position as a European based life sciences pharmaceutical company. The Board would like to thank Mr. Hayes for his valued contribution during his tenure on the board, and wish him well for the future.